



# Anti-PD-1/IL-7v immunocytokine (BICKI®IL7v) favors proliferation & survival of TCF1+ stem like memory T cells and a durable in vivo efficacy in monotherapy or using combinatorial strategies

Aurore Morello, Justine Durand, Margaux Seité, Isabelle Girault, Géraldine Teppaz, Virginie Thepenier, Cécile Batty, Ariane Desselle, Emmanuelle Wilhelm, Kevin Biteau, Marine Mallocci, Stéphanie Neyton, Vanessa Gauttier, Caroline Mary, Nicolas Poirier


## BICKI®IL7, an optimized design for selective cis-potential of PD-1+IL-7R+ T cells




## 1/ BICKI®IL-7v promotes long-term proliferation of stem-like TCF1+ CD8 T cells




## 2/ Efficient monotherapy efficacy in vivo by promoting infiltration and proliferation of TCF1+ memory stem-like CD8 T cells




BICKI®IL7 efficacy relies on proliferation of Infiltrating T cells but also induces recruitment of fresh T cells into the TME





BICKI®IL7v favors specific infiltration and proliferation of TCF1+ stem-like T cells



BICKI®IL7v overcomes T cell exclusion



## 3/ High synergistic efficacy of BICKI®IL7v in combination with chemotherapeutic or Tyrosine Kinase Inhibitor agents



## Conclusion

**BICKI®IL7v Anti PD-1/IL7v immunocytokine**  
To sustain a durable PD-1+ stem like CD8 T cell response

- Optimized molecule for Cis targeting activity
- Conserved high PD-1 binding and PD-1/PD-L1 antagonist activity
- Allows a selective delivery of IL-7 on PD-1+ cells
- Promotes proliferation of PD-1+ CD127+ TCF1+ stemness T cells
- High in vivo anti tumor efficacy in monotherapy or combo in PD-1 sensitive, resistant syngeneic and humanized models (8 different models)

Contacts

nicolas.poirier@ose-immuno.com  
aurore.morello@ose-immuno.com